The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Polymorphism of the N -acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis
Abstract
Antituberculosis drug-induced hepatitis is one of the most prevalent drug-induced liver injuries. Isoniazid is the major drug incriminated in this hepatotoxicity. Isoniazid is mainly metabolized to hepatotoxic intermediates by N-acetyltransferase (NAT). However, the association of polymorphic NAT acetylator status and antituberculosis drug-induced hepatitis is debatable. To determine whether acetylator status is a risk factor for antituberculosis drug-induced hepatitis, we genotyped NAT2 in 224 incident tuberculosis patients who received antituberculosis treatment. Antituberculosis drug-induced hepatitis was diagnosed based on a positive isoniazid rechallenge test and exclusion of viral hepatitis. Acetylator status was determined by genotyping NAT2 in patients using a polymerase chain reaction with restriction fragment length polymorphism. Univariate analysis and logistic regression analysis were used to evaluate the risk factors of isoniazid-induced hepatitis. Thirty-three patients (14.7%) were diagnosed with antituberculosis drug-induced hepatitis. Slow acetylators had a higher risk of hepatotoxicity than rapid acetylators (26.4% vs. 11.1%, P = .013). Among patients with hepatotoxicity, slow acetylators had significantly higher serum aminotransferase levels than rapid acetylators. Logistic regression showed that slow-acetylator status (odds ratio [OR], 3.66; 95% CI, 1.58-8.49; P = .003) and age (OR, 1.09; 95% CI, 1.04-1.14; P < .001) were the only 2 independent risk factors for antituberculosis drug-induced hepatitis. In conclusion, slow-acetylator status of NAT2 is a significant susceptibility risk factor for antituberculosis drug-induced hepatitis. Additionally, slow acetylators are prone to develop more severe hepatotoxicity than rapid acetylators. Regular monitoring of serum aminotransferase levels is mandatory in patients receiving antituberculosis treatment, especially in slow acetylators.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
Criteria of drug-induced liver disorders
(1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90124-a · Cited by 1,106
Isoniazid Liver Injury: Clinical Spectrum, Pathology, and Probable Pathogenesis
MITCHELL, J. R., ZIMMERMAN, H. J., ISHAK, K. G., THORGEIRSSON, U. P., TIMBRELL, J. A., SNODGRASS, W. R., & NELSON, S. D. (1976) · Annals of Internal Medicine · doi:10.7326/0003-4819-84-2-181 · Cited by 505
BLUM, M., GRANT, D. M., McBRIDE, W., HEIM, M., & MEYER, U. A. (1990) · DNA and Cell Biology · doi:10.1089/dna.1990.9.193 · Cited by 435
Isoniazid-Associated Hepatitis in 114 Patients
Black, M., Mitchell, J. R., Zimmerman, H. J., Ishak, K. G., & Epler, G. R. (1975) · Gastroenterology · doi:10.1016/s0016-5085(19)32568-5 · Cited by 370
Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.
De, K., Snider, D. E., & Caras, G. J. (1978) · PubMed · doi:10.1164/arrd.1978.117.6.991 · Cited by 368
Lee, W. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331706 · Cited by 305
Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid.
Ryan, D. E., Ramanathan, L., Iida, S., Thomas, P. E., Haniu, M., Shively, J. E., Lieber, C. S., & Levin, W. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)88984-0 · Cited by 304
Mitchell, J. R., Thorgeirsson, U. P., Black, M., Timbrell, J. A., Snodgrass, W. R., Potter, W. Z., Jollow, D. J., & Keiser, H. R. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197518170 · Cited by 300
Bell, D. A., Taylor, J. A., Butler, M. A., Stephens, E. A., Wiest, J., Brubaker, L. H., Kadlubar, F. F., & Lucier, G. W. (1993) · Carcinogenesis · doi:10.1093/carcin/14.8.1689 · Cited by 292
Drug–Induced Liver Injury: Mechanisms and Test Systems
Bissell, M. D., Gores, G. J., Laskin, D. L., & Hoofnagle, J. H. (2001) · Hepatology · doi:10.1053/jhep.2001.23505 · Cited by 267
Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.
Pande, J. N., Singh, S. P., Khilnani, G. C., Khilnani, S., & Tandon, R. K. (1996) · Thorax · doi:10.1136/thx.51.2.132 · Cited by 244
PHARMACOGENETICS IN PEDIATRICS
Leeder, J. S., & Kearns, G. L. (1997) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70463-6 · Cited by 234
Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection
Wong, W.-M., Wu, P.-C., Yuen, M.-F., Cheng, C.-C., Yew, W.-W., Wong, P.-C., Tam, C.-M., Leung, C.-C., & Lai, C.-L. (2000) · Hepatology · doi:10.1002/hep.510310129 · Cited by 231
Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene
Lin, H. J., Han, C.-Y. E., Lin, B. K., & Hardy, S. (1994) · Pharmacogenetics · doi:10.1097/00008571-199406000-00003 · Cited by 165
Parthasarathy, R., Sarma, G. R., Janardhanam, B., Ramachandran, P., Santha, T., Sivasubramanian, S., Somasundaram, P. R., & Tripathy, S. P. (1986) · Tubercle · doi:10.1016/0041-3879(86)90003-6 · Cited by 150
Hein, D. W., Doll, M. A., Rustan, T. D., & Ferguson, R. J. (1995) · PubMed · Cited by 130
Rb, B. (1979) · JAMA · doi:10.1001/jama.241.12.1239 · Cited by 123
Sherlock, S. (1995) · Gut · doi:10.1136/gut.37.3.447-b · Cited by 118
Sarma, G. R., Immanuel, C., Kailasam, S., Narayana, A. S. L., & Venkatesan, P. (1986) · PubMed · doi:10.1164/arrd.1986.133.6.1072 · Cited by 116
Anti-tuberculosis medication and the liver: dangers and recommendations in management
Thompson, N., Caplin, M. E., Hamilton, M., Gillespie, S. H., Clarke, S. W., Burroughs, A. K., & McIntyre, N. (1995) · European Respiratory Journal · doi:10.1183/09031936.95.08081384 · Cited by 99
Hwang, S., WU, J., LEE, C., Yen, F., Lu, C., LIN, T., & LEE, S. (1997) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1997.tb00353.x · Cited by 91
Self-citationIsoniazid-rifampin-induced hepatitis in hepatitis B carriers
Wu, J., Lee, S., Yeh, P.-F., Chan, C., Wang, Y.-J., Huang, Y., Tsai, Y., Lee, P.-Y., Ting, L., & Lo, K. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90846-s · Cited by 87
Self-citationRisk Factors for Isoniazid (INH)-Induced Liver Dysfunction
Dickinson, D. S., Bailey, W. C., Hirschowitz, B. I., Soong, S.-J., Eidus, L., & Hodgkin, M. M. (1981) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-198109000-00012 · Cited by 84
Gurumurthy, P., Krishnamurthy, M. S., Nazareth, O., Parthasarathy, R., Sarma, G. R., Somasundaram, P. R., Tripathy, S. P., & Ellard, G. A. (1984) · PubMed · doi:10.1164/arrd.1984.129.1.58 · Cited by 81
Ethanol-induced increase in drug acetylation in man and isolated rat liver cells.
Olsen, H., & Mørland, J. G. (1978) · BMJ · doi:10.1136/bmj.2.6147.1260 · Cited by 68
Elevated Serum Aminotransferase Induced by Isoniazid in Relation to Isoniazid Acetylator Phenotype
Yamamoto, T., Suou, T., & Hirayama, C. (1986) · Hepatology · doi:10.1002/hep.1840060223 · Cited by 66
Rothman, N., Stewart, W. F., Caporaso, N., & Hayes, R. B. (1993) · PubMed · Cited by 58
MECHANISMS OF DRUG-INDUCED LIVER DISEASE
DeLeve, L. D., & Kaplowitz, N. (1995) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(21)00228-4 · Cited by 58
Zielińska, M., Bodalski, J., Mianowska, K., Niewiarowski, W., Rębowski, G., Skrętkowicz, J., & Sekulska, M. (1998) · Pharmacy World & Science · doi:10.1023/a:1008664707825 · Cited by 32
GENETIC PREDISPOSITION TO DRUG-INDUCED LIVER DISEASE
Fontana, R. J., & Watkins, P. B. (1995) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(21)00229-6 · Cited by 11
Cited by
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Bernal, W., Auzinger, G., Dhawan, A., & Wendon, J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60274-7 · Cited by 996
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Navarro, V. J., & Senior, J. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052270 · Cited by 811
Metadata
- Authors
- Huang, Y.-S., Chern, H.-D., Su, W.-J., Wu, J.-C., Lai, S.-L., Yang, S.-Y., Chang, F.-Y., & Lee, S.-D.
- Venue
- Hepatology
- Published
- 2002-04
- Volume
- 35
- Issue
- 4
- Pages
- 883-889
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2095134596
- Cited by
- 432
- References
- 32
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.